BioSpace News Archive

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2021 financial results and provided a corporate update.

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) (“Protagonist” or “the Company”) today reported its financial results for the second quarter ended June 30, 2021, and an overview of recent company progress.

IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will participate in the panel discussion, “Only Have Eyes For You - Ophthalmic Gene Therapy,” at the 2021 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 11 at 8:00 a.m. Eastern Time.

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today reported results for the second quarter period ended June 30, 2021, and provided a corporate overview and business update.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2021 and updated its sales guidance for the year ending December 31, 2021.

AtriCure, Inc., a leading innovator in treatments for atrial fibrillation and left atrial appendage management, announced second quarter 2021 financial results.

STAAR Surgical Company, a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, reported financial results for the second quarter ended July 2, 2021.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, reported unaudited financial results for the quarter ended June 30, 2021.

Kadmon Holdings, Inc. announced that the National Comprehensive Cancer Network® added REZUROCKTM tablets to its NCCN Clinical Practice Guidelines in Oncology for Hematopoietic Cell Transplantation in the Pre-Transplant Recipient Evaluation and Management of Graft-Versus-Host Disease.

Corvion – developer of fully implanted mechanical circulatory support devices – announced that William Cohn, MD and Sean Morris have been appointed to the company’s Board of Directors, effective immediately.